Eugenol Inhibits Ox-LDL-Induced Proliferation and Migration of Human Vascular Smooth Muscle Cells by Inhibiting the Ang II/MFG-E8/MCP-1 Signaling Cascade
DOI: https://doi.org/10.2147/jir.s446960
IF: 4.5
2024-02-03
Journal of Inflammation Research
Abstract:Jia-Huan He, 1, &ast Xiang-Jun Li, 2, &ast Shi-Peng Wang, 1 Xia Guo, 1 Hao-Xuan Chu, 1 Han-Chi Xu, 1 Yu-Shi Wang 1 1 Department of Cardiology, The First Hospital of Jilin University, Changchun, 13000, People's Republic of China; 2 Department of Experimental Pharmacology and Toxicology, College of Pharmacy, Jilin University, Changchun, 130000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yu-Shi Wang, Department of Cardiology, The First Hospital of Jilin University, Changchun, 13000, People's Republic of China, Tel +86 18643199605, Email Objective: In this study, we investigated the effect and mechanism of action of eugenol on oxidized low-density lipoprotein (ox-LDL)-induced abnormal proliferation and migration of human vascular smooth muscle cells (HVSMCs). Methods: HVSMCs were treated with 100 ug/mL ox-LDL for 24 hours to establish a cell model. After 1-hour pretreatment, eugenol at concentrations of 5, 25, and 50 uM was added. Cell viability was assessed using an MTT assay, PCNA expression was detected using Western blot, cell cycle distribution was analyzed using flow cytometry, and cell migration ability was evaluated using wound healing and Transwell migration assays. To investigate the mechanisms, Ang II receptors were inhibited by 1000 nM valsartan, MFG-E8 was knocked down by shRNA, MCP-1 was inhibited by siRNA, and MFG-E8 was overexpressed using plasmids. Results: The findings from this study elucidated the stimulatory impact of ox-LDL on the proliferation and functionality of HVSMCs. Different concentrations of eugenol effectively mitigated the enhanced activity of HVSMCs induced by ox-LDL, with 50 uM eugenol exhibiting the most pronounced inhibitory effect. Flow cytometry and Western blot results showed ox-LDL reduced G1 phase cells and increased PCNA expression, while 50 uM eugenol inhibited ox-LDL-induced HVSMC proliferation. In wound healing and Transwell migration experiments, the ox-LDL group showed larger cell scratch filling and migration than the control group, both of which were inhibited by 50 uM eugenol. Inhibiting the Ang II/MFG-E8/MCP-1 signaling cascade mimicked eugenol's effects, while MFG-E8 overexpression reversed eugenol's inhibitory effect. Conclusion: Eugenol can inhibit the proliferation and migration of ox-LDL-induced HVSMCs by inhibiting Ang II/MFG-E8/MCP-1 signaling cascade, making it a potential therapeutic drug for atherosclerosis. Keywords: Ang II, eugenol, HVSMCs, MFG-E8, MCP-1, ox-LDL Cardiovascular disease has one of the highest incidence and mortality rates in the world. It is primarily caused by atherosclerosis. 1 Numerous factors contribute to the incidence and development of atherosclerosis, with the primary initiating factors being abnormal lipid deposition and oxidation. 2 When low-density lipoprotein is oxidized and modified to form oxidized low-density lipoprotein (ox-LDL), it can activate endothelial cells and vascular smooth muscle cells (VSMCs) to produce various inflammatory and chemotactic factors, thereby encouraging monocytes to aggregate using the vascular endothelium and engulf ox-LDL to form plaques. 3 Therefore, inhibiting ox-LDL-induced inflammation and VSMC activation is crucial in preventing atherosclerosis. Despite the success of lipid-lowering therapy in the treatment and prevention of cardiovascular diseases, the risk of cardiovascular disease remains high, necessitating the search for additional treatment targets. Anti-inflammatory treatment has emerged as a new strategy for anti-atherosclerosis treatment because of the central role inflammation plays in the disease. 4 There is mounting evidence that the Ang II signaling cascade contributes significantly to the onset and progression of atherosclerosis. Ang II can promote abnormal proliferation, migration, and inflammatory response of VSMCs. 5–7 MFG-E8 and MCP-1, two key components of the Ang II signaling cascade, have been confirmed to be involved in this process. 8 MFG-E8 is a glycoprotein that exists in various cells and plays a significant role in the development of vascular aging-related diseases by promoting VSMC proliferation, migration, phenotype transformation, and inflammatory response. 9–12 Ang II or MFG-E8 administration in vitro has been shown to upregulate the expression of MCP-1 and promote VSMC migration. 8 Therefore, inhibiting the Ang II/MFG-E8/MCP-1 signaling axis is of immense significance in preventing the activation of VSMCs. Eugenol is a phenolic compound that is commonly found in Chinese herbs, and possesses anti-inflammatory an -Abstract Truncated-
immunology